IQV) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 10.3% year on year to $4.36 billion ... Is now the time to buy IQV? Find out in our full research report (it’s free for active Edge members).
What Happened?. Shares of clinical research company IQVIA (NYSE. IQV) fell 8.5% in the morning session after the company issued a weak full-year 2026 profit forecast that fell below Wall Street expectations ... We’ve identified the next one ... More News ... .
IQV) reported Q4 CY2025 results exceeding the market’s revenue expectations, with sales up 10.3% year on year to $4.36 billion ... IQVIA (IQV) Q4 CY2025 Highlights. ... IQV) provides clinical research ...
At the core of the showcase is Arspura’s IQV system, an airflow architecture that integrates inclined airflow guidance, multi-vortex capture structures, and an air curtain configuration within a single hood design.